CodeMap® Compliance Briefing: July 29, 2011
Last week, we discussed the CMS Meeting held July 18 to discuss setting reimbursement rates for new codes included on the Medicare Clinical Lab Fee Schedule. In particular, we reviewed some of the recommendations made by stakeholder participants concerning drug screening coding and reimbursement. On that same day, CMS also convened a meeting concerning the newly created codes for genetic tests and molecular pathology. As most of our subscribers are aware, the AMA plans to add approximately 92 analyte specific codes to the 2012 CPT® for reporting molecular pathology procedures. In 2013, the AMA plans to add another 9 codes representing another 78 molecular pathology analytes. Immediately following the July 18 meeting mentioned earlier, CMS held a second meeting concerning the reimbursement for these codes. In that meeting we learned CMS' plans for 2012, as well as the associated recommendations from stakeholders concerning these new codes. Today, we will discuss these important developments,....
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
CPT copyright 2021 American Medical Association. All rights reserved.
* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid
Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related
to any use, nonuse, or interpretation of information contained in this product.